Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Chubb
Dow
Moodys
Daiichi Sankyo
Covington
QuintilesIMS
Deloitte
Julphar

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GENOTROPIN

« Back to Dashboard

Clinical Trials for Genotropin

Trial ID Title Status Sponsor Phase Summary
NCT00119769 The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients Completed Pfizer Phase 4 The purpose of this study is to investigate the effect of low-dose human growth hormone therapy on immune status and fat morphology.
NCT00119769 The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients Completed Hvidovre University Hospital Phase 4 The purpose of this study is to investigate the effect of low-dose human growth hormone therapy on immune status and fat morphology.
NCT00136032 Growth Hormone Administration and Its Effects on Cardiovascular Risk Factors in Growth Hormone Deficient Women Completed Massachusetts General Hospital N/A The purpose of the study is to evaluate the effects of growth hormone replacement on women with growth hormone deficiency. Growth hormone deficiency means the body no longer produces growth hormone due to a tumor or some kind of disease of the brain in an area called the pituitary/hypothalamic region. This is the area of the brain where growth hormone is normally produced. We, the researchers at Massachusetts General Hospital, will establish the effects of growth hormone replacement on cardiovascular parameters (laboratory tests, the flexibility of the arteries, changes in heart rate) in women with growth hormone deficiency. Our goal is to see if this therapy: - has effects on women's cardiovascular risk markers (special blood tests which indicate how healthy the heart and arteries are) - has effects on women's types and levels of various substances circulating in their blood - in women affects the stiffness of their arteries and heart rate variability in parallel with changes in cardiovascular risk markers - has different effects depending on whether women are pre or post menopausal. Participation in this study is expected to last approximately 12 months.
NCT00174408 Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational Age Completed Pfizer Phase 3 The primary objective is to evaluate, if Genotonorm (Genotropin) increases linear growth in short children born SGA. Safety of the drug is a main objective as well. The growth promoting effect of two different dosages is compared. The effect of long-term treatment on final height is evaluated (according to several amendments)
NCT00174421 Treatment Of Short Stature With Genotropin In Children Born Small For Gestational Age Until Final Height Completed Pfizer Phase 3 This trial evaluates whether long-term treatment with Genotropin normalizes final (adult) height in short children born small for gestational age
NCT00209235 Albright Hereditary Osteodystrophy: Growth Hormone Trial and Cognitive/Behavioral Assessments Recruiting Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 2/Phase 3 We, the researchers, have found that growth hormone deficiency is very common in patients with pseudohypoparathyroidism type 1a, which falls under the broader condition termed Albright hereditary osteodystrophy. Patients with pseudohypoparathyroidism type 1a typically are short and obese. Some of these patients are not short during childhood, but due to a combination of factors, they end up short as adults. We are evaluating the effect of growth hormone treatment in those patients with pseudohypoparathyroidism type 1a who are found to be growth hormone deficient. We hypothesize that growth hormone deficiency may contribute to the short stature and obesity found in this condition. We are also evaluating the effect of growth hormone on patients with pseudohypoparathyroidism type 1a who are not growth hormone deficient (i.e., growth hormone sufficient) in those who had been on study drug through R01 FD003409 or who meet the criteria of idiopathic short stature or SGA. We are also evaluating neurocognitive and psychosocial functioning in participants with AHO in order to determine the specific impairments that are most common in the condition and to determine the best approach toward management. Funding source -- Growth hormone study: FDA OOPD [R01 FD003409 (which has ended) and R01 FD002568 (which has ended)] Cognitive/behavior: NICHD R21 HD078864
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Genotropin

Condition Name

Condition Name for Genotropin
Intervention Trials
Growth Hormone Deficiency 6
Growth Disorder 3
Healthy 3
Traumatic Brain Injury 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Genotropin
Intervention Trials
Dwarfism, Pituitary 12
Endocrine System Diseases 7
Brain Injuries 5
Dwarfism 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Genotropin

Trials by Country

Trials by Country for Genotropin
Location Trials
United States 29
Japan 12
Spain 4
Korea, Republic of 4
France 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Genotropin
Location Trials
Texas 3
New York 3
Ohio 2
Colorado 2
Maryland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Genotropin

Clinical Trial Phase

Clinical Trial Phase for Genotropin
Clinical Trial Phase Trials
Phase 4 5
Phase 3 13
Phase 2/Phase 3 2
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Genotropin
Clinical Trial Phase Trials
Completed 19
Recruiting 6
Active, not recruiting 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Genotropin

Sponsor Name

Sponsor Name for Genotropin
Sponsor Trials
Pfizer 16
University of Aarhus 2
The University of Texas Medical Branch, Galveston 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Genotropin
Sponsor Trials
Industry 27
Other 18
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
UBS
Queensland Health
Farmers Insurance
Healthtrust
Deloitte
Baxter
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.